



## Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*

Monaldi Arch Chest Dis 2024 [Online ahead of print]

*To cite this Article:*

Mohan S, Kumar R, Ish P, et al. **Diffuse alveolar hemorrhage: a retrospective study from a tertiary care center.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.3203

 ©The Author(s), 2024  
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



## **Diffuse alveolar hemorrhage: a retrospective study from a tertiary care center**

Sanchit Mohan, Rohit Kumar, Pranav Ish, Rajnish Kaushik,  
Tanmaya Talukdar, Neeraj Gupta, Nitesh Gupta

Department of Pulmonary Medicine, VMMC & Safdarjung Hospital, New Delhi, India

**Correspondence:** Nitesh Gupta, Department of Pulmonary Medicine, room number 612, super speciality block, VMMC & Safdarjung Hospital, New Delhi, 110029, India.

E-mail: [niteshgupta2107@gmail.com](mailto:niteshgupta2107@gmail.com)

**Contributions:** SM, RK, PI, RKK, TT, NGU, NG, involved in literature search, planning, conduct, writing the original draft of manuscript, literature search, and editing; NG, RK, involved in review and editing. All the authors have agreed with the submitted manuscript.

**Conflict of interest:** the authors declare that they have no conflicts of interest regarding current study.

**Ethics approval and consent to participate:** no ethical clearance required.

**Informed consent:** written informed consent taken.

**Funding:** none.

**Availability of data and materials:** the clinical data and the study materials available from the corresponding author on reasonable request.

## **Abstract**

Diffuse alveolar hemorrhage (DAH) is characterized by a syndrome of alveolar bleeding, a fall in hemoglobin, and respiratory failure. It can occur because of various immunologic and non-immunologic conditions. The etiology of DAH is important, as treatment varies with the etiology. This retrospective observational study evaluates the diverse etiologies, time to diagnosis from symptom onset, management strategies, and outcome of DAH in a span of 12 months at our tertiary care center. A total of 8 patients were identified with 8 different etiologies. 6/8 (75%) patients had immunologic causes, and 2/8 (25%) had non-immunologic causes of DAH. 6/8 (75%) patients were females, the mean time to DAH diagnosis was 4.25 months from symptom onset, 6/8 (75%) patients improved, and 2/8 (25%) died due to complications. It is necessary to differentiate between the etiologies of DAH and establish an early diagnosis to plan management and improve outcomes.

**Key words:** pulmonary hemorrhage, alveolar hemorrhage, hemoptysis, bronchoscopy, pulmonary-renal syndromes.

## **Introduction**

Diffuse Alveolar Hemorrhage (DAH) is characterized by bleeding in the alveoli of the lungs, resulting in the accumulation of blood within the lung parenchyma, leading to potentially life-threatening respiratory compromise. It is associated with a spectrum of diverse etiologies including autoimmune diseases, vasculitis, infectious agents, cardiac cause and drugs [1].

The most common conditions associated with DAH includes anti-glomerular basement membrane antibodies (Anti-GBM), antineutrophil cytoplasm antibody (ANCA) related vasculitis, systemic lupus erythematosus (SLE) and rarely anti-phospholipid antibody syndrome (APLA), idiopathic pulmonary hemosiderosis (IPH) and other collagen vascular diseases may be also found [2]. Among ANCA associated vasculitis Granulomatosis with polyangiitis (GPA) is the common cause of DAH followed by microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) [3].

Patients with DAH typically present with symptoms such as cough, hemoptysis, dyspnea, hypoxemia with new pulmonary infiltrate on chest radiology and anemia. Although the presentation may vary, diagnosis often involves a combination of clinical assessment, laboratory tests, imaging studies, bronchoscopy, and sometimes lung biopsy to confirm the presence of alveolar haemorrhage [4]. DAH is a life-threatening condition with a poor prognosis; about 20%-50% of hospital mortality has been reported [2]. Hence, rapid diagnosis and early initiation of treatment is necessary to prevent mortality.

Treatment includes immunosuppressive therapy, including systemic steroids and steroid-sparing agents. These may be harmful in patients where the cause of DAH is due to infection; therefore, the infection must be ruled out before starting immunosuppressive therapy [2].

This one-year study explores the diverse etiologies, clinical presentation, time to diagnosis from symptom onset, management strategies and outcome of DAH. By examining individual cases, we aim to shed light on the varied causes, diagnostic challenges, and treatment approaches encountered in the management of DAH.

## **Materials and Methods**

It was a retrospective observational study analyzing medical records of patients admitted to the Department of Pulmonary Critical Care and Sleep, at a tertiary care center between April 2023 to March 2024 (12 months).

### ***Inclusion criteria***

All patients who were admitted to the Department of Pulmonary, Critical Care and Sleep at a tertiary care center for suspected DAH.

### ***Exclusion criteria***

Patients who were repeatedly admitted for DAH with same etiology. Patients with hemorrhage due to bronchial etiology. Patients who were already on treatment for DAH before the initiation of this study.

Criteria to define DAH: Compatible clinical picture of hemoptysis/anemia, pulmonary infiltrates on chest radiograph and bronchoalveolar lavage (BAL) fluid either showing progressive hemorrhagic returns on serial aliquots or  $\geq 20\%$  hemosiderin laden macrophages on cytological examination [2]. The STROBE guidelines for observational studies were used for reporting (Figure 1).

### **Results**

A total of 1080 patients were admitted in the department of pulmonary, critical care and sleep, out of which 120 had suspected DAH, 100 patients had endobronchial cause of hemoptysis and were excluded a total of 20 cases were diagnosed as DAH. 12/20 patients had recurrent admission hence 8 patients were considered in final evaluation.

The mean age of presentation was 39.87 years. 6/8 (75%) of patients in our study were female. Anemia was present in all patients (100%) at the time of presentation. 6/8 (75%) patients presented with hemoptysis. The mean time for diagnosis of DAH was 4.25 months from the symptom onset (15 days to 12 months). The predominant high-resolution computed tomography (HRCT) finding was ground glass opacities (GGO) followed by consolidation; cavitation was seen in one patient. 4/8 (50%) patients presented with acute kidney injury (AKI), explained by raised creatinine and urea. 4/8 (50%) of patients had glomerulonephritis at the time of presentation, explained by the presence of dysmorphic RBCs in urine.

Histopathological diagnosis on trans-bronchial lung biopsy (TBLB) was achieved in 6/8 (75%) patients; 4/6 (66.66%) patients had capillaritis, and 2/6 (33.33%) patients had bland hemorrhage of varied etiologies. 6/8 (75%) patients had an immune cause of DAH like SLE, ANCA-associated, APLA-associated and anti-GBM-associated DAH, whereas 2/8 (25%) patients had a non-immune cause like IPH and drug-induced. 6/8 (75%) patients improved and are in follow-up, and 2/8

(25%) patients died due to infection (Figures 2 and 3). Both the patients who died had immune-mediated cause of DAH. The clinical profile of all 8 cases is presented in Table 1.

## **Discussion**

DAH associated with hemoptysis should be differentiated from other causes of hemoptysis like infections, bronchiectasis, neoplasm [5]. DAH is classified into immune and non-immune, immune causes of DAH are associated with capillaritis whereas non-immune causes have bland hemorrhage on histopathology [5]. DAH associated with capillaritis is characterized by destruction of alveolar capillaries and neutrophilic infiltration, fibrinoid necrosis of the alveolar tissue and capillary's perivascular interstitium [5]. ANCA-associated vasculitis, SLE, anti-GBM disease, Collagen vascular disease, and post lung transplantation (Acute rejection) cause immune mediated DAH whereas DAH associated with bland hemorrhage, occurs due to leakage of RBCs into the alveoli without destruction or inflammation of alveolar capillaries, venules, or arterioles.<sup>5</sup> It occurs due to Idiopathic Pulmonary Hemosiderosis (IPH), and drug-induced.

SLE and anti-GBM can induce DAH with capillaritis and bland pulmonary haemorrhage [5]. One-third of the patients with DAH does not have hemoptysis as a presenting complaint. Our findings are in concordance with a case series by De Prost N et al. [6], one-fourth of patients (25%) in a present study did not present with hemoptysis. Anemia is usually present in patients with DAH; our findings concord with the study by Alexandre, A. T et al. [7], who showed 19/24 (79%) of patients with DAH present with anemia.

Chest radiology in the present study showed GGO, consolidation and cavitation. 8/8 (100%) patients had one or the other radiological abnormalities; however, in a study by Lbelda SM et al. [8], 20 to 50% of cases of DAH can have normal radiology in the acute stage. These findings indicate that a high index of suspicion is required in the absence of radiological abnormalities and normal hemoglobin levels.

In their study, Kumasaka S et al. described a hyperdense consolidation sign characterized by a consolidation density higher than that of the aorta [9]. The specificity of the hyperdense consolidation sign was 100% in distinguishing DAH from another alveolar disease. In the present study, 4/8 (50%) patients had hyperdense consolidation on chest radiology. A hemorrhagic Bronchoalveolar Lavage (BAL) that does not clear after sequential aliquots indicates DAH. While BAL can diagnose DAH, it cannot identify its underlying cause but can help rule out infectious and neoplastic causes [1].

In the present study, BAL diagnosed DAH in all cases, and infections were excluded in all patients. Systemic vasculitis is most commonly associated with DAH among immune causes [7]. In the present study, 3/8 (37.5%) patients had DAH secondary to ANCA-associated vasculitis, and 6/8 (75%) patients had an immune-related DAH. In a study by Quadrelli et al. [3], 75% of patients of DAH due to immune mechanisms were secondary to ANCA-associated vasculitis, GPA being most common among them. Connective tissue diseases (CTD) accounted for the rest. In the present study, only 1 patient had CTD-related DAH.

Anti-phospholipid antibody syndrome (APS) is an autoimmune disease characterized by thromboembolic events with obstetric morbidity along with anti-phospholipid antibodies. Pulmonary Thromboembolism (PTE) and pulmonary artery hypertension (PAH) are frequent pulmonary complications [10]. Rarely DAH has been found to be associated with APS [11]. In the present study, 1/8 (12.5%) patients had APS as a cause of DAH, and APS was diagnosed after the diagnosis of DAH. In a case series by Deane KD et al. 9/79(11%) patients had DAH as the initial presentation of APS [12].

On the other hand, a study by Scheiman Elazary A et al. and Cartin-Ceba R et al. in 18 and 13 patients of APS median time to DAH onset was 5.9 and 5.8 years, respectively, after the diagnosis of APS [13,14]. APS patients in the present study had capillaritis on histopathology; however, the largest case series on APS-associated DAH by Cartin-Ceba R et al. showed only 3/18 (16%) patients had capillaritis [14].

Treatment of immune DAH includes pulse methylprednisolone (MPS) followed by oral prednisolone 1mg/kg (maximum 60 mg) for 1 week followed by tapering along with other immunosuppressive therapy i.e. Cyclophosphamide or Rituximab [3,14]. 6/8 (75%) patients in the present study had an immune mediated cause of DAH 5/6 (83%) was treated with pulse MPS 1g/day for 3 days along with intravenous rituximab 375mg/m<sup>2</sup> weekly or 4 weeks followed by maintenance 1gm rituximab 6 monthly, 1/6 (17%) patient could not be treated as patient succumbed to infection before treatment could be initiated.

Non-Immune mediated causes of DAH include infections (dengue, leptospirosis, malaria, Staphylococcus aureus, Mycoplasma, Legionella, cytomegalovirus, adenovirus, invasive aspergillosis, Strongyloides), heart diseases (mitral stenosis, left ventricular dysfunction, left atrial myxoma), drug-induced (amiodarone, anti-platelets; cannabis smoking) and idiopathic pulmonary hemosiderosis [7]. 2 patients in the present study had a bland hemorrhage on histopathology, 1 was associated with a drug (Clopidogrel) who improved after stopping the culprit drug.

The other was associated with Idiopathic Pulmonary Hemosiderosis, which improved with Tab. Prednisolone 0.75mg/kg and iron supplements. BAL was done in both the cases, and infections were ruled out. There was no evidence of cardiac abnormality on echo cardiography. A case report published by Onuk T et al. has shown the occurrence of DAH on the second day of clopidogrel use; however, in the present study, it occurred after 3 years of use [15]. Soriano R et al. published a case report in 2021 describing clopidogrel as a culprit of DAH after 6 months of its use [16]. In both the cases published in the literature, histopathology suggested bland hemorrhage; stopping the culprit agent has led to the resolution of symptoms.

IPH may be present with celiac disease known as Lane-Hamilton syndrome [17], where the patient presented with DAH and on further evaluation, he was diagnosed with celiac disease and was treated with a gluten-free diet however, in the present case there was no history of diarrhea and serum Anti Tissue Transglutaminase antibody titers were 1U/ml (Normal <3U/ml), hence the diagnosis of isolated IPH was made.

Treatment of acute DAH without respiratory failure requiring invasive mechanical ventilation (IMV) is oral prednisolone 0.5mg/kg to 0.75mg/kg for 4-8 weeks followed by tapering; however, treatment in patients requiring IMV is pulse dose of methylprednisolone (500–2000 mg/day for 3–5 days) followed by oral prednisone 0.5–1 mg/kg/day [18].

Case report published by Iwasaki K et al. diagnosed isolated IPH without TBLB and treated with MPS 1gm/day for 3 days followed by MPS 80mg/day for 9 days, and the patient was successfully weaned off from non-invasive ventilation on the 10th day [19]. 6/8 (75%) patients improved from the current study; one died of complications of immunosuppressive therapy, and the other died due to complications of the disease. Immunosuppressive therapy remains the mainstay of treatment in patients with immune-mediated DAH. Reported mortality in DAH is 20%-50% [20]. DAH secondary to SLE has shown 50% mortality [20]. Our findings concord with N. de Prost et al. [5], who stated 25% mortality in patients with DAH. De Prost, N. et al. reported 17.9% mortality with immune DAH [21].

### ***Clinical outcomes and prognosis***

Despite the varied etiologies and treatment approaches, outcomes differed among the cases. While some patients achieved resolution of symptoms and disease control with treatment, others faced complications such as infections leading to adverse outcomes. The heterogeneity in outcomes underscores the importance of early recognition, prompt intervention, and individualized management strategies based on underlying pathology.



### ***Limitations***

Our study is limited by its retrospective nature and the small sample size. The diversity in etiologies highlights the complex nature of DAH, necessitating a multidisciplinary approach involving pulmonologists, rheumatologists, and intensivists for optimal management.


### **Conclusions**

In conclusion, our study underscores the diverse etiologies and clinical presentations associated with DAH. Timely recognition of underlying conditions and tailored therapeutic interventions can help improving outcomes in patients presenting with this challenging clinical entity.


## References

1. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. *Chest* 2010;137:1164-71.
2. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. *Am J Kidney Dis* 2002;39:42-7.
3. Quadrelli S, Dubinsky D, Solis M, et al. Immune diffuse alveolar hemorrhage: clinical presentation and outcome. *Respir Med* 2017;129:59-62.
4. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. *Clin Chest Med* 2004;25:583-92.
5. Park MS. Diffuse alveolar hemorrhage. *Tuberc Respir Dis* 2013;74:151-62.
6. de Prost N, Parrot A, Picard C, et al. Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. *Eur Respir J* 2010;35:1303-11.
7. Alexandre AT, Vale A, Gomes T. Diffuse alveolar hemorrhage: How relevant is etiology? *Sarcoidosis Vasc Diffuse Lung Dis* 2019;36:47-52.
8. Ibelda SM, Geftter WB, Epstein DM, Miller WT. Diffuse pulmonary hemorrhage: a review and classification. *Radiology* 1985;154:289-97.
9. Kumasaka S, Kumasaka Y, Jingu A, Tsushima Y. Diagnostic value of “hyperdense consolidation sign” as a characteristic new computed tomography sign of diffuse alveolar hemorrhage. *Sci Rep* 2022;12:21143.
10. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. *N Engl J Med* 2018;378:2010-21.
11. Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. *Semin Arthritis Rheum* 2015;44:652-7.
12. Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. *Semin Arthritis Rheum* 2005;35:154-65.
13. Scheiman Elazary A, Cohen MJ, Amar S, et al. Pulmonary hemorrhage in antiphospholipid antibody syndrome. *J Rheumatol* 2012;39:1628-31.
14. Cartin-Ceba R, Peikert T, Ashrani A, et al. Primary antiphospholipid syndrome–associated diffuse alveolar hemorrhage. *Arthritis Care Res* 2014;66:301-10.
15. Onuk T, İpek G, Karataş MB, et al. Diffuse alveolar hemorrhage after clopidogrel use. *Balkan Med J* 2016;33:719-20.
16. Soriano R, Al-Rawaf S, Diab K. Diffuse alveolar haemorrhage: a rare complication of clopidogrel use. *BMJ Case Rep* 2021;14:e244314.


17. Khilnani GC, Tiwari P, Goyal A, Singh L, Arora A, Guleria R. A rare case of pulmonary alveolar hemorrhage with cardiomyopathy. *Chest* 2018;142:463A.
18. Saha BK. Idiopathic pulmonary hemosiderosis: A state of the art review. *Respir Med* 2021;176:106234.
19. Iwasaki K, Matsuzawa Y, Wakabayashi H, et al Diffuse alveolar haemorrhage with suspected idiopathic pulmonary hemosiderosis and decrease in lung diffusing capacity and chronic respiratory failure *BMJ Case Rep* 2021;14:e242901.
20. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome. *Medicine* 1997;76:192-202.
21. de Prost N, Parrot A, Cuquemelle E, et al. Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. *Respir Med* 2021;106:1021-32.



**Figure 1. Flow of patient selection.**



**Figure 2. a) High resolution CT thorax (HRCT) showing Left lower lobe consolidation (black thick arrow) with GGO nodule in right middle and lower lobe; b) (thin orange arrow) CT pulmonary angiography showing saddle thrombus in main pulmonary artery; c) purpura on right upper limb; d) HRCT showing GGO in bilateral upper lobe (red thin arrow); e) HRCT showing cavitating masses in lower lobe (red thick arrow); f) sequential BAL showing hemorrhagic returns.**



**Figure 3. a) HRCT showing RUL consolidation (black thin arrow); b) HRCT showing LUL consolidation of same patient after 6 months (red thin arrow); c) bland hemorrhage (eosin and hematoxylin stain original magnification 10x); d) HRCT showing bilateral upper lobe consolidation left > right (black thick arrow); e) HRCT showing bilateral consolidation right>left of same patient 2 years back; f) histopathology of TBLB showing neutrophilic inflammation suggestive of capillaritis (eosin and hematoxylin stain, original magnification 10x).**

**Table 1. Clinical profile of all 8 cases.**

Case	Age (years) /sex	Hemoglobin (g/dL)	Creatinine (mg/dL)	Hemoptysis	Urine dysmorphic RBC	HRCT findings	TBLB	Time to diagnosis	Diagnosis	Treatment/Outcome
1	75/M	9.6	0.8	Yes	Negative	GGO in RLL	Bland hemorrhage	6 months	Drug-Induced	Stop Clopidogrel/ Improved
2	17/F	9	2.0	No	Negative	Left consolidation, cardiomegaly, bilateral pleural effusion; saddle thrombus in MPA	capillaritis	40 days	SLE	Enoxaparin, steroids, Rituximab/ Succumbed to infection
3	50/F	7.0	0.6	Yes	Positive	Bilateral pleural effusion; right > left GGOs	capillaritis	15 days	EGPA with skin manifestation (Purpura)	Steroids, Rituximab/ Improved
4	30/F	6.7	0.7	No	Negative	Bilateral upper lobe consolidation, surrounding GGO	capillaritis	1 month	Anti-phospholipid antibody syndrome	Anticoagulation, steroids, Rituximab, Apixaban/ Improved
5	20/F	7.5	1.8	No	Positive	Cavitating lesions in bilateral lung fields	capillaritis	3 months	GPA	Steroids, Rituximab/ Improved
6	35/F	6.8	0.6	Yes	Negative	Left upper lobe consolidation	Bland hemorrhage	12 months	Idiopathic Pulmonary Hemosiderosis	Prednisolone/ Improved
7	66/M	11.0	2.6	Yes	Positive	Bilateral GGO and consolidation	Not done	2 months	Life-threatening Microscopic polyangiitis	Steroids, Rituximab/ Improved
8	26/F	7.0	2.2	Yes	Positive	Bilateral GGO predominantly in lower lobes	Not done	8 months	Goodpasture syndrome	Could not be treated/ Succumbed to infection